Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Amarin (Nasdaq: AMRN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Amarin's business and see what CAPS investors are saying about the stock right now.

Amarin facts

Headquarters (founded) Dublin (1989)
Market Cap $1.84 billion
Industry Biotechnology
Management Chairman/CEO Joseph Zakrzewski
President/CFO John Thero
Cash/Debt $129.5 million / $516,000
Competitors Merck (NYSE: MRK)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 92% of the 161 members who have rated Amarin believe the stock will outperform the S&P 500 going forward. These bulls include Icebone284 and All-Star zzlangerhans, who is ranked in the top 2% of our community.

Just last month, Icebone24 succinctly summed up the Amarin bull case: "Blockbuster drug phaseIII results plus baby boomer population in need of [triglyceride] lowering drug means huge market potential."

Over the next five years, in fact, Amarin is expected to grow its bottom line at a whopping rate of 74% annually. That's naturally much faster than big pharma plays such as GlaxoSmithKline (NYSE: GSK) (11%), Merck (4%), and Pfizer (NYSE: PFE) (3%).

CAPS All-Star zzlangerhans elaborates on the Amarin bull case:

I'll never understand why the company flirted with bankruptcy after years of failed trials of AMR101 in Huntington's, Parkinson's, and niacin flush before addressing the more obvious indication of hypertriglyceridemia. But after strongly positive results from two phase III trials, FDA approval seems highly likely. Partnership, buyout, or not I believe Amarin will rise back toward 20 once the NDA process is under way.

What do you think about Amarin, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline and Pfizer. The Fool owns shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.